Editorial Focus

The Evolving Psychedelic Paradigm

Non-Drug Treatment Landscape for GAD: Cognitive Therapies
news

Non-Drug Treatment Landscape for GAD: Cognitive Therapies

October 14, 2026

CBT has the strongest evidence among cognitive therapies for GAD, while support for applied relaxation and metacognitive therapy is less certain.
GAD Is More Common in Women, but Evidence Around Pregnancy and Menopause Remains Unclear
news

GAD Is More Common in Women, but Evidence Around Pregnancy and Menopause Remains Unclear

October 14, 2026

GAD is more common in women, but evidence that pregnancy or menopause alters GAD itself remains limited because studies mostly measured anxiety symptoms.
Two Investigational Paths in GAD: Company-Reported Results on DT120 ODT and SNTX-2643
news

Two Investigational Paths in GAD: Company-Reported Results on DT120 ODT and SNTX-2643

September 29, 2026

DT120 (lysergide) and SNTX-2643 are advancing as investigational GAD treatments at different stages of development, with neither yet approved by the FDA.

Recent JCP Articles on Evolving Psychedelics

JCP
The Regulatory Maze of Ketamine and Psychedelics with Benjamin Brody, MD
Podcast

The Regulatory Maze of Ketamine and Psychedelics with Benjamin Brody, MD

September 8, 2026

Benjamin Brody, MD, discusses ketamine’s REMS-regulated future, esketamine safety, dysphoric dissociation, and what psilocybin approval means for psychiatry.
,
JCP
Hallucinogen–Psychosis Associations Are Confounded by Baseline Psychiatric History
Original Research ▶ Video

Hallucinogen–Psychosis Associations Are Confounded by Baseline Psychiatric History

June 10, 2026

Apparent associations between hallucinogen use and psychosis appear largely attributable to baseline psychiatric comorbidities rather than direct causal effects.
, , , et al
JCP
Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression
Original Research

Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression

June 3, 2026

Mebufotenin (GH001) demonstrated rapid and significant improvements in depressive symptoms and remission of postpartum depression.
, , , et al
Image shows Dr. David Feifel in a lab coat; text discusses long-term psilocybin outcomes for treatment-resistant depression.

Behind the Manuscript: The Psychedelic Renaissance and Treatment-Resistant Depression with David Feifel, MD, PhD

Dr. David Feifel discusses psilocybin’s breakthrough potential for treatment-resistant depression, the psychedelic renaissance, and preparing for a new era in psychiatry.

Listen to the Podcast

Recent PCC Articles on Evolving Psychedelics

PCC
Psychological Adverse Effects of Psychedelic Use
Rounds in the General Hospital

Psychological Adverse Effects of Psychedelic Use

June 25, 2026

This case-based review explores psychological adverse effects of psychedelic use, covering risk factors, trauma history, phenomenology, and evidence-based management strategies for clinicians.
, , , et al
PCC
Medical Complications of Psychedelics
Rounds in the General Hospital

Medical Complications of Psychedelics

June 23, 2026

This case-based review covers acute complications, drug interactions, and long-term safety across psilocybin, MDMA, ketamine, and ibogaine, with practical guidance for clinicians.
, , , et al
PCC
Precision Psychiatry for Depression Treatment
Narrative Review

Precision Psychiatry for Depression Treatment

September 9, 2025

Novel precision medicine tools in depression aim to identify the optimal treatment for each patient and have the potential to significantly improve depression management by guiding treatment selection for…
, , , et al

More Articles on Evolving Psychedelics

Generalized Anxiety Disorder After 65: What the Screening Evidence Does and Does Not Cover
news

Generalized Anxiety Disorder After 65: What the Screening Evidence Does and Does Not Cover

September 23, 2026

Anxiety screening in adults 65 and older lacks sufficient evidence, as data on GAD screening tool accuracy and treatment effectiveness remain limited.
Who Gets Excluded from Psychedelic Trials in GAD, and Why
news

Who Gets Excluded from Psychedelic Trials in GAD, and Why

September 16, 2026

Psychedelic trials in generalized anxiety disorder exclude participants based on cardiac risk from 5-HT2B agonism, personal and family psychiatric history, and psychotropic washout requirements.
Measurement-Based Care in Generalized Anxiety Disorder
news

Measurement-Based Care in Generalized Anxiety Disorder

September 16, 2026

Measurement-based care in GAD rests on validated tools and guideline timepoints, but no trial has yet isolated the effect of measurement itself.
Improved but Not Recovered: The Relapsing Course of Generalized Anxiety Disorder
news

Improved but Not Recovered: The Relapsing Course of Generalized Anxiety Disorder

August 28, 2026

GAD follows a chronic, relapsing course in which comorbidity reduces recovery odds and antidepressant discontinuation roughly triples relapse risk.
Safety Across Classic Psychedelics in GAD: What Three Investigational Programs Show So Far
news

Safety Across Classic Psychedelics in GAD: What Three Investigational Programs Show So Far

August 28, 2026

Early safety data from lysergide, psilocybin, and deuterated DMT GAD trials show predominantly mild-to-moderate, session-concentrated adverse events across all three programs.
The Weakened Brake: Circuit and Synaptic Biology in Generalized Anxiety Disorder
news

The Weakened Brake: Circuit and Synaptic Biology in Generalized Anxiety Disorder

August 1, 2026

GAD reframed as a disorder of maladaptive synaptic and circuit plasticity, linking amygdala-prefrontal dysregulation to slow treatment response and relapse.
The Receptor at the Center of Psychedelic Therapies for GAD
news

The Receptor at the Center of Psychedelic Therapies for GAD

August 1, 2026

Classic psychedelics target 5-HT2A receptors, not serotonin transporters. Slow dissociation and intracellular signaling may explain lasting effects seen in GAD.
2026 Congress Coverage: The Persistence Problem in GAD and Treatment-Resistant Depression
news

2026 Congress Coverage: The Persistence Problem in GAD and Treatment-Resistant Depression

July 27, 2026

Real-world GAD claims data show 18% treatment persistence at one year; TRD Phase 3 baseline data reveal severe, chronic illness after multiple failed pharmacotherapy trials.
Psychedelics Are Advancing in GAD, but None Are Yet Approved
news

Psychedelics Are Advancing in GAD, but None Are Yet Approved

July 16, 2026

Two psychedelics show early GAD trial signals—DT120 and psilocybin—but no agent is approved for anxiety. Interpreting evidence by stage, not label, matters
How Generalized Anxiety Disorder Presents, and Why It Is Often Missed
news

How Generalized Anxiety Disorder Presents, and Why It Is Often Missed

July 7, 2026

GAD frequently presents with somatic symptoms, leading to missed diagnoses; only 34% of cases are correctly identified in primary care, with a median 9-year treatment delay.
Generalized Anxiety Disorder: A Persistent Burden Despite Standard Treatments
news

Generalized Anxiety Disorder: A Persistent Burden Despite Standard Treatments

July 7, 2026

GAD affects ~20M US adults, yet one-third achieve remission with first-line SSRIs/SNRIs and no new mechanism has been approved since 2007; the treatment gap persists.
JCP
Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation
Original Research ▶ Video

Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation

May 13, 2026

A single psilocybin dose with psychological support was associated with rapid, large, and durable reductions in suicidal ideation and depressive symptoms.
, , , et al

Subscribe to read
more articles

Subscribe